Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3247177 | 0.99 | CA1 (0.49) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL3240155 | 0.87 | LMNA (0.56) | CA1CA2CA9KMT2AKEAP1 | |
| SCHEMBL3246831 | 0.84 | CA2 (0.52) | CA1CA2HTTCA9KMT2A | |
| Hydrochloric Acid SCHEMBL3264480 | 0.83 | CA2 (0.51) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL2532555 | 0.81 | CHRNA7 (0.47) | HTTKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3247945 | 0.75 | KMT2A (0.55) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL540915 | 0.74 | CA1 (0.85) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL11793140 | 0.74 | CA1 (0.85) | CA1CA2HTTCA9KMT2A | |
| Hydrochloric Acid SCHEMBL3247483 | 0.74 | KMT2A (0.54) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL7124336 | 0.72 | MAPT (0.75) | CA1CA2HTTCA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | claimed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | claimed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | claimed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | claimed |
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| US-7662808-B2 | N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | CHRNA6, CHRNA10, CHRNA2 | CA1 4303/4885CA2 3055/4885HTT 555/4885 |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | CHRNA6, CHRNA10, CHRNA2 | CA1 4307/4885CA2 3023/4885HTT 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.